Don't want to miss the best from Business Standard?
Dr Reddy’s Laboratories has moved higher by 2.2% at Rs 1,879 on NSE after the company announced that it has launched Zoledronic acid injection in the US market following approval by the US health regulator.
“The company has launched Zoledronic acid injection (5 mg/100 ml) in the US market on April 3, 2013, following the approval by the United States Food and Drugs Administration (USFDA),” Dr Reddy’s Laboratories said in a press release.
The product is a generic version of Reclast (zoledronic acid) injection in the same strength. The company’s injection is available in single use vial for intravenous infusion.
According to IMS health, the Reclast brand had total US sales of approximately $335 million for the most recent twelve months ending February 2013.
The stock opened at Rs 1,835 and hit a low of Rs 1,831 in morning deals. A combined 94,657 shares have changed hands on the counter till 1056 hours on NSE and BSE.
“The company has launched Zoledronic acid injection (5 mg/100 ml) in the US market on April 3, 2013, following the approval by the United States Food and Drugs Administration (USFDA),” Dr Reddy’s Laboratories said in a press release.
The product is a generic version of Reclast (zoledronic acid) injection in the same strength. The company’s injection is available in single use vial for intravenous infusion.
According to IMS health, the Reclast brand had total US sales of approximately $335 million for the most recent twelve months ending February 2013.
The stock opened at Rs 1,835 and hit a low of Rs 1,831 in morning deals. A combined 94,657 shares have changed hands on the counter till 1056 hours on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%